Please login to the form below

Not currently logged in
Email:
Password:

AZ discontinues asthma medicine

AstraZeneca is to discontinue production of an inhaled version of its asthma medication Pulmicort due to 'manufacturing issues'

AstraZeneca (AZ) is to discontinue production of the pressurised metered dose inhaler (pMDI) version of its asthma medication Pulmicort (budesonide), in both its 100µg and 200µg doses, due to 'manufacturing issues'.

The company said the problem is due to 'product-specific processes and components', the combination of which was used solely in the manufacturing of Pulmicort pMDI.

The decision to discontinue the product was not related to the active ingredient of the medicine, budesonide - a corticosteroid also used in AZ's nasal inhalant, Rhinocort, for conditions such as hayfever, and the controlled-release capsule Entocort for Crohn's disease.

Other unaffected products include AZ's Pulmicort Turbuhaler, Pulmicort Respules and Pulmicort Flexhaler.

David Smith, executive vice president, Global Operations and IS, AstraZeneca, said the company had "exhausted all potential solutions" in its efforts to solve the technical problems and to continue supplying the product.

"[I]t is in the patient's best interest to find an alternative medication as soon as possible," continued Smith, with AZ stating that it is working with regulatory authorities and healthcare professionals to help patients on Pulmicort pMDI to switch treatments.

Patients currently on the medication will be able to finish any current supplies they have remaining.

7th March 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics